Fig. 3

The effect of α5 integrin on senescence of the obese hASCs. a Representative images of the expression of α5 integrin and α-SMA in ITGA5 siRNA-treated and control siRNA-treated obese hASCs was determined by immunofluorescence. Histogram showing the difference of the relative intensity of α5 integrin and α-SMA in the field. The number of fields was 20–21 for the expression of α5 integrin and α-SMA in each group respectively. Data are presented as the means ± SEM. Scale bars, 50 μm. b Representative images of the expression of α5 integrin and YAP in ITGA5 siRNA-treated and control siRNA-treated obese hASCs was determined by immunofluorescence. Histogram showing the difference of the relative intensity of α5 integrin in the field and YAP normalized to DAPI each nuclear of cells. The number of fields for the expression of α5 integrin was 16–17 in each group respectively. The number of cells for the expression of YAP was 265–284 in each group respectively. Data are presented as the means ± SEM. Scale bars, 50 μm. c Representative images of SA-β-Gal staining in ITGA5 siRNA-treated obese hASCs and control siRNA-treated obese hASCs. Histogram showing the difference of the positive area percentage of SA-β-Gal. The number of fields for SA-β-Gal staining was 17 in each group respectively. Data are presented as the means ± SEM. Scale bars, 25 μm. d The relative mRNA levels of cell cycle inhibitors genes and SASP-related genes in ITGA5 siRNA-treated obese hASCs and control siRNA-treated obese hASCs were determined by quantitative RT-PCR. The relative expression of each gene was normalized against 18S rRNA. Data are presented as the means ± SEM. Significant difference by unpaired two-tailed paired t test. A.U. Arbitrary Unit; ITGA5, α5 integrin